

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.: 10/800,917  
Applicant: Gertrud HOTTEN  
Filed: March 16, 2004  
TC/A.U.: 1647  
Examiner: David S. ROMEO

Docket No. : 2923-609  
Customer No.: 06449  
Confirmation No. : 2179

**SUBMISSION OF TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir:

Further to our response filed on February 11, 2008, enclosed are two  
Terminal Disclaimers for the above application.

In the event this paper is not considered to be timely filed, the Applicant respectfully petitions for an appropriate extension of time. Any fee for such an extension together with any additional fees that may be due with respect to this paper, may be charged to Counsel's Deposit Account No. 02-2135.

Respectfully submitted,

By



Monica Chin Kitts  
Attorney for Applicant  
Registration No. 36,105  
ROTHWELL, FIGG, ERNST & MANBECK  
1425 K. Street, Suite 800  
Washington, D.C. 20005  
Telephone: (202) 783-6040

MCK/cb

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/800,917  
Applicant : Gertrud HOETTEN et al  
Filed : March 16, 2004  
TC/A.U. : 1647  
Examiner : David S. Romeo

Docket No. : 2923-609  
Customer No. : 06449  
Confirmation No. : 2179

**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL  
DOUBLE PATENTING REJECTION OVER PENDING APPLICATIONS**

Director of the United States Patent  
and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The owner, BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA, of Heidelberg, Germany owns 100 percent interest in the instant applications hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173 as shortened by any terminal disclaimer filed prior to the grant of any patent granted on pending Application Serial Nos. 10/472,389, filed on March 22, 2002 and 11/080,494 filed March 16, 2005, of any patents on the pending applications. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on pending Application Serial Nos. 10/472,389 and 11/080,494 are commonly owned. This

U.S. Serial Number 10/800,917

Page 2

agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA the owner does not disclaim the terminal part of any patent granted on the instant applications that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its grant.

Statement under 37 C.F.R. 3.73(b)


BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA is the assignee of 100 percent interest in the instant application, by virtue of an assignment recorded in the U.S. Patent and Trademark Office at Reel 015037 and Frame 0901 and Reel 013261 and Frame 0624.

The undersigned, whose title is supplied below, is empowered to act on behalf of the owner.

Declaration

The undersigned hereby declares that all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

BIOPHARM GESELLSCHAFT ZUR  
BIOTECHNOLOGISCHEN ENTWICKLUNG  
VON PHARMAKA

By:   
Signature

Typed Name: Dr. JENS POHL

Typed Title: CHIEF EXECUTIVE OFFICER

Date: 4<sup>th</sup> of March, 2008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. : 10/800,917  
Applicant : Gertrud HOETTEN et al  
Filed : March 16, 2004  
TC/A.U. : 1647  
Examiner : David S. Romeo

Docket No. : 2923-609  
Customer No. : 06449  
Confirmation No. : 2179

TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL  
DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Director of the United States Patent  
and Trademark Office  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

The owner, BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA, of Heidelberg, Germany owns 100 percent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as shortened by any terminal disclaimer, of prior Patent No. 6,120,760. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. § 1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer.

Statement under 37 C.F.R. 3.73(b)

BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA, is the assignee of 100 percent interest in the instant application, by virtue of an assignment recorded in the U.S. Patent and Trademark Office at Reel 008282 and Frame 0845.


The undersigned, whose title is supplied below, is empowered to act on behalf of the owner.

Declaration

The undersigned hereby declares that all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and

further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

BIOPHARM GESELLSCHAFT ZUR  
BIOTECHNOLOGISCHEN ENTWICKLUNG VON  
PHARMAKA,

By:   
Signature

Typed Name: DR. JENS POHL

Typed Title: CHIEF EXECUTIVE OFFICER

Date: 4<sup>th</sup> of March, 2008